Spyre Therapeutics Stock Today
| SYRE Stock | 28.70 1.48 5.44% |
Performance1 of 100
| Odds Of DistressLess than 27
|
Spyre Therapeutics is trading at 28.70 as of the 12th of October 2024, a 5.44% up since the beginning of the trading day. The stock's lowest day price was 27.15. Spyre Therapeutics has about a 27 % chance of experiencing some form of financial distress in the next two years of operation and did not have a very good performance during the last 90 trading days. Spyre Therapeutics symbol was changed from AGLE on 28th of November 2023. Equity ratings for Spyre Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 12th of September 2024 and ending today, the 12th of October 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 7th of April 2016 | Category Healthcare | Classification Health Care |
Spyre Therapeutics is entity of United States. It is traded as Stock on NASDAQ exchange. The company has 50.92 M outstanding shares of which 8.64 M shares are at this time shorted by private and institutional investors with about 13.59 trading days to cover. More on Spyre Therapeutics
Spyre Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Older Symbol | AGLE | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Principal CEO | Cameron DPHIL | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Biotech (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Biotech, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Spyre Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Spyre Therapeutics' financial leverage. It provides some insight into what part of Spyre Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Spyre Therapeutics (SYRE) is traded on NASDAQ Exchange in USA. It is located in 221 Crescent Street, Waltham, MA, United States, 02453 and employs 50 people. Spyre Therapeutics was previously known as Aeglea Bio Therapeutics and was traded on NASDAQ Exchange under the symbol AGLE. Spyre Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.39 B. Spyre Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 50.92 M outstanding shares of which 8.64 M shares are at this time shorted by private and institutional investors with about 13.59 trading days to cover.
Spyre Therapeutics generates negative cash flow from operations
Check Spyre Therapeutics Probability Of Bankruptcy
Ownership AllocationSpyre Therapeutics shows a total of 50.92 Million outstanding shares. The majority of Spyre Therapeutics outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Spyre Therapeutics to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Spyre Therapeutics. Please pay attention to any change in the institutional holdings of Spyre Therapeutics as this could imply that something significant has changed or is about to change at the company. Also note that roughly one million eight hundred twenty-two thousand nine hundred twenty-five invesors are currently shorting Spyre Therapeutics expressing very little confidence in its future performance.
Check Spyre Ownership Details
Spyre Therapeutics Historical Income Statement
Spyre Stock Against Markets
Spyre Therapeutics Corporate Management
| James JD | Consultant | Profile | |
| Janet MBA | Senior Operations | Profile | |
| Eric McIntyre | Vice Relations | Profile | |
| Deanna MD | Senior Development | Profile | |
| CFE CPA | Vice Controller | Profile | |
| Justin LaFountaine | Senior Development | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Spyre Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Spyre Stock refer to our How to Trade Spyre Stock guide.You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Spyre Therapeutics. If investors know Spyre will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Spyre Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 10.89 | Return On Assets (0.32) | Return On Equity (1.02) |
The market value of Spyre Therapeutics is measured differently than its book value, which is the value of Spyre that is recorded on the company's balance sheet. Investors also form their own opinion of Spyre Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Spyre Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Spyre Therapeutics' market value can be influenced by many factors that don't directly affect Spyre Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Spyre Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Spyre Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Spyre Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.